

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 December 2020 (30.12.2020)



(10) International Publication Number
WO 2020/263695 A1

(51) International Patent Classification:

A61K 31/4439 (2006.01) A61P 3/10 (2006.01)
C07D 405/14 (2006.01)

(21) International Application Number:

PCT/US2020/038617

(22) International Filing Date:

19 June 2020 (19.06.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/868,117 28 June 2019 (28.06.2019) US
62/904,906 24 September 2019 (24.09.2019) US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly
Corporate Center, Indianapolis, Indiana 46206-6288 (US).

(72) Inventors: **COATES, David Andrew**; c/o Eli Lilly
and Company, P.O. Box 6288, Indianapolis, Indiana
46206-6288 (US). **FIELDS, Todd**; c/o Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US). **HO, Joseph Daniel**; c/o Eli Lilly and Company, P.O.
Box 6288, Indianapolis, Indiana 46206-6288 (US). **QU,
Fucheng**; c/o Eli Lilly and Company, P.O. Box 6288, Indi-
anapolis, Indiana 46206-6288 (US).

(74) Agent: **CHOLEWA, Brian C.** et al.; c/o Eli Lilly and Com-
pany, P.O. Box 6288, Indianapolis, Indiana 46206-6288
(US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONISTS



(57) Abstract: In an embodiment, the present invention provides a compound of the formula: or a pharmaceutically acceptable salt thereof, and methods of using this compound for treating type II diabetes mellitus.



WO 2020/263695 A1